Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lb Pharmaceuticals (LBRX) Cash from Investing Activities (2024 - 2026)

Lb Pharmaceuticals' quarterly Cash from Investing Activities came in at -$32000.0 in Q1 2026, down 100.64% year-on-year from $5.0 million in Q1 2025, and up 20.0% quarter-over-quarter from -$40000.0 in Q4 2025.

Lb Pharmaceuticals has reported Cash from Investing Activities for 3 years, with the latest figure at -$32000.0 in Q1 2026.

  • For the quarter ending Q1 2026, Cash from Investing Activities fell 100.64% year-over-year to -$32000.0; the trailing twelve-month figure through Mar 2026 stood at $18.4 million (changed N/A YoY), and the FY2025 full-year result was -$39.9 million, down 271.68% from the prior year.
  • Cash from Investing Activities for Q1 2026 stood at -$32000.0, up from -$40000.0 in the prior quarter.
  • The five-year high for Cash from Investing Activities was $13.5 million in Q4 2024, with the low at -$40000.0 in Q4 2025.
  • Average Cash from Investing Activities over 3 years is $4.6 million, with a median of $2.5 million recorded in 2025.
  • Year-over-year, Cash from Investing Activities plunged 100.3% in 2025 and slumped 100.64% in 2026.
  • Tracing LBRX's Cash from Investing Activities over 3 years: stood at $13.5 million in 2024, then tumbled by 100.3% to -$40000.0 in 2025, then advanced by 20.0% to -$32000.0 in 2026.
  • The last three Cash from Investing Activities figures came in at -$32000.0 (Q1 2026), -$40000.0 (Q4 2025), and $5.0 million (Q1 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Investing Activities (Qtr)
1 Quantum Biopharma 1,216,509.61 Bn 1,216,509.61 Bn - -2.89 Mn
2 Alterity Therapeutics 764,224.41 Bn 764,224.38 Bn - -
3 Legend Biotech 2,716.00 Bn 2,715.71 Bn 242.10 Mn 638.50 Mn
4 Nanobiotix 2,248.83 Bn 2,248.77 Bn - -
5 Akari Therapeutics 1,951.18 Bn 1,951.17 Bn - -
6 Vertex Pharmaceuticals 113.69 Bn 106.44 Bn 2.59 Bn -431.90 Mn
7 Evaxion A 64.16 Bn 64.14 Bn - -
8 Regeneron Pharmaceuticals 63.94 Bn 55.18 Bn 3.31 Bn -428.90 Mn
9 Alnylam Pharmaceuticals 40.13 Bn 37.12 Bn 959.66 Mn -25.54 Mn
10 Lb Pharmaceuticals 789.92 Mn 789.92 Mn - -32,000.00

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 -32,000.00
Mar 31, 2026 -32,000.00
Dec 31, 2025 -40,000.00
Dec 31, 2025 -40,000.00
Mar 31, 2025 4.98 Mn
Mar 31, 2025 4.98 Mn
Dec 31, 2024 13.54 Mn
Dec 31, 2024 13.54 Mn